Small molecule · Inhibitor of activin A receptor type I (ALK2) (ACVR1) · developed by Mirum
Zilurgisertib is an oral, selective small-molecule inhibitor of ALK2 (ACVR1), including wild-type and the pathogenic R206H mutant form. By blocking ALK2 signaling in the bone morphogenetic protein pathway, it reduces endochondral bone formation. It is studied in fibrodysplasia ossificans progressiva.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 9, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05090891 | Phase 2 | Fibrodysplasia Ossificans Progressiva (FOP) | Recruiting | INCY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fibrodysplasia Ossificans Progressiva (FOP)
Updated Nov 22, 2026.